Porphyria, Acute Intermittent clinical trials
The registry lists 21 studies for Porphyria, Acute Intermittent across more than 10 countries. 3 are recruiting or about to start. 19 of them are mainly about Porphyria, Acute Intermittent (how this is decided). Per ClinicalTrials.gov, last updated 2026-09-10.
Get an email when these change. Save the Porphyria, Acute Intermittent studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Alnylam Pharmaceuticals (6) · The University of Texas Medical Branch, Galveston (3) · Nordlandssykehuset HF (2) · Digna Biotech S.L. (2) · Cycle Pharmaceuticals Ltd. (1) · National Institute of Cardiology, Warsaw, Poland (1) · The American Porphyrias Expert Collaborative (1) · National Center for Research Resources (NCRR) (1)
What is being tested here
Drugs under test in Porphyria, Acute Intermittent studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Givosiran | 0 | 1 | 4 |
| Hemin | 0 | 0 | 2 |
| Chlorpromazine | 0 | 0 | 1 |
| Heme arginate | 0 | 0 | 1 |
| Tin mesoporphyrin | 0 | 0 | 1 |
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 2
- Dec 2026Acute Porphyria Biomarkers for Disease Activity · The University of Texas Medical Branch, Galveston
- Oct 2027Clinical Research on Acute Intermittent Porphyria and the Use of Carbohydrate-Rich Diet as a Treatment · Nordlandssykehuset HF
Who these studies take
Of the 3 Porphyria, Acute Intermittent studies recruiting now, 3 (100%) set no upper age limit and 0 (0%) stop at 75 or younger. 2 (67%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 1 (33%) | 1 (33%) |
| 18 | 3 (100%) | 3 (100%) |
| 30 | 3 (100%) | 3 (100%) |
| 40 | 3 (100%) | 3 (100%) |
| 50 | 3 (100%) | 3 (100%) |
| 65 | 3 (100%) | 3 (100%) |
| 75 | 3 (100%) | 3 (100%) |
| 85 | 3 (100%) | 3 (100%) |
Across all 21 studies, recruiting or not: 29% stop at 75 or younger and 29% at 65; 33% take children; 0% are for women only and 0% for men only; 14% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 21 of 21. search them.
- Identification of Acute Intermittent Porphyria Modifying GenesRecruitingNCT055021331 country
- Longitudinal Study of the PorphyriasRecruitingNCT015611571 country
- Clinical Research on Acute Intermittent Porphyria and the Use of Carbohydrate-Rich Diet as a TreatmentRecruitingNCT06273644Not applicable2 countries
- Acute Porphyria Biomarkers for Disease ActivityActive, not recruitingNCT029354001 country
- Panhematin for Prevention of Acute Attacks of PorphyriaTerminatedNCT02922413Phase 21 country
- Controlled Trial of Panhematin in Treatment of Acute Attacks of PorphyriaCompletedNCT02180412Phase 21 country
- Expanded Access Protocol of Givosiran for Patients With Acute Hepatic PorphyriaApproved for marketingNCT04056481
- Dental Health, Diet, Inflammation and Biomarkers in Patients With Acute Intermittent Porphyria(AIP)Active, not recruitingNCT016176421 country
- ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute Hepatic Porphyrias (AHP)CompletedNCT03338816Phase 318 countries
- Acute Intermittent Porphyria Related Abnormalities in Cardiovascular SystemCompletedNCT058821361 country
- A Study to Evaluate Long-term Safety and Clinical Activity of Givosiran (ALN-AS1) in Patient With Acute Intermittent Porphyria (AIP)CompletedNCT02949830Phase 1/23 countries
- Clinical Diagnosis of Acute PorphyriaCompletedNCT015685541 country
- Evidence-based Assessment of Medication Sensitivity in Acute Hepatic PorphyriaCompletedNCT039062141 country
- A Study to Investigate the Interaction Between Givosiran and a 5-probe Drug Cocktail in Patients With Acute Intermittent Porphyria (AIP)CompletedNCT03505853Phase 11 country
- INSIGHT-AHP: A Study to Characterize the Prevalence of Acute Hepatic Porphyria (AHP) in Patients With Clinical Presentation and History Consistent With AHPTerminatedNCT035472971 country
- A Phase 1 Study of Givosiran (ALN-AS1) in Patients With Acute Intermittent Porphyria (AIP)CompletedNCT02452372Phase 13 countries
- Porphozym in the Treatment of Acute Attacks in AIPCompletedNCT00418795Phase 2/31 country
- Assessment of Intra-subject Variability in the Bioavailability of Chlorpromazine HydrochlorideCompletedNCT02943213Phase 11 country
- Phase I Gene Therapy Clinical Trial Using the Vector rAAV2/5-PBGD for the Treatment of Acute Intermittent PorphyriaCompletedNCT02082860Phase 11 country
- Observational Study of Acute Intermittent Porphyria PatientsCompletedNCT020767631 country
- Phase I/II Study of Heme Arginate and Tin Mesoporphyrin for Acute PorphyriaCompletedNCT00004789Phase 1/2